301
|
Lughezzani G, Sun M, Perrotte P, Jeldres C, Budaus L, Thuret R, Liberman D, Arjane P, Widmer H, Shariat SF, Graefen M, Guazzoni G, Montorsi F, Karakiewicz PI. 24 THE EUROPEAN NETWORK FOR THE STUDY OF ADRENAL TUMORS STAGING SYSTEM IS PROGNOSTICALLY SUPERIOR TO THE INTERNATIONAL UNION AGAINST CANCER STAGING SYSTEM: A NORTH AMERICAN VALIDATION. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
302
|
Lughezzani G, Jeldres C, Budäus L, Shariat SF, Sun M, Liberman D, Thuret R, Arjane P, Widmer H, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI. 1797 TUMOR SIZE IS ASSOCIATED WITH THE RATE OF SYNCHRONOUS METASTASES IN PATIENTS WITH SMALL RENAL CELL TUMORS. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.1721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
303
|
Liberman D, Isbarn H, Jeldres C, Badaus L, Lughezzani G, Sun M, Shariat SF, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. 431 PERSONALIZED MANAGEMENT OF UPPER URINARY TRACT UROTHELIAL CARCINOMA: THE EFFECT OF AGE ON CANCER-SPECIFIC MORTALITY. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
304
|
Lughezzani G, Karakiewicz PI, Bigot P, Perrotte P, Crépel M, Rioux-Leclercq N, Catros-Quemener V, Moulinoux JP, Bouet F, Cipolla B, Patard JJ. The prognostic value of erythrocyte polyamines in the preoperative evaluation of patients with renal cell carcinoma. Eur J Cancer 2010; 46:1927-35. [PMID: 20335019 DOI: 10.1016/j.ejca.2010.02.052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2009] [Revised: 12/07/2009] [Accepted: 02/26/2010] [Indexed: 11/27/2022]
Abstract
INTRODUCTION Polyamines, spermine and spermidine, are ubiquitous polycationic structures, which are essential for cell proliferation and differentiation. We tested whether spermine and spermidine could improve the prognostic ability of six established preoperative predictors of cancer-specific mortality (CSM) after partial or radical nephrectomy for renal cell carcinoma (RCC). MATERIALS AND METHODS Overall, 385 patients with clinical stages T(1-3), M(0-1) RCC were treated with radical or partial nephrectomy at a single institution between 1990 and 2007. Kaplan-Meier plots depicted CSM after stratification according to spermine and spermidine levels (dichotomised to above and below the median value). Univariable and multivariable Cox regression models tested the prognostic ability of continuously coded spermine and spermidine levels in preoperative CSM predictions. Covariates consisted of pre-treatment T stage, M stage, age, gender and symptom classification. RESULTS The 5-year CSM-free survival of patients with spermine levels < or =4.5 and >4.5 nmol/8x10(9) erythrocytes were, respectively, 79.5% and 65.0%. Similarly, the 5-year CSM-free survival of patients with spermidine levels < or =9.0 and >9.0 nmol/8x10(9) erythrocytes were, respectively, 81.1% and 63.7%. In multivariable analyses addressing CSM after surgery, both spermine (p< or =0.002) and spermidine (p< or =0.001) achieved independent predictor status and improved the accuracy of established preoperative CSM predictors by 2.1% (p<0.001). CONCLUSIONS Circulating polyamine levels may significantly improve the prognostic value of established determinants of CSM in patients with RCC of all stages prior to nephrectomy. External validation of our findings is required prior to implementation in clinical practice.
Collapse
|
305
|
Sun M, Lughezzani G, Alasker A, Isbarn H, Jeldres C, Shariat SF, Budäus L, Lattouf JB, Valiquette L, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Comparative Study of Inguinal Hernia Repair After Radical Prostatectomy, Prostate Biopsy, Transurethral Resection of the Prostate or Pelvic Lymph Node Dissection. J Urol 2010; 183:970-5. [DOI: 10.1016/j.juro.2009.11.036] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2009] [Indexed: 11/16/2022]
|
306
|
Lughezzani G, Sun M, Budäus L, Thuret R, Shariat SF, Perrotte P, Karakiewicz PI. Effect of the number of biopsy cores on prostate cancer detection and staging. Future Oncol 2010; 6:381-90. [DOI: 10.2217/fon.10.4] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Digital rectal examination, serum concentration of prostate cancer-specific antigen and transrectal ultrasound-guided biopsies are currently the main diagnostic tools to detect evidence of prostate cancer. Different prostatic biopsy strategies have been proposed in order to achieve an optimal prostate cancer detection rate and an accurate characterization of prostate cancer stage and grade. We examined the role of the number of biopsy cores on prostate cancer detection rates at initial and repeat biopsies. Moreover, we examined the relationship between the number of biopsy cores and the detection of insignificant prostate cancer. Finally, we reviewed the ability of biopsy cores in predicting prostate cancer stage and grade at radical prostatectomy. We relied on a PubMed systematic review of the contemporary English language literature using the terms ‘prostate cancer’, ‘diagnosis’, ‘transrectal ultrasound’ and ‘prostate biopsy’.
Collapse
|
307
|
Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer 2010; 115:5680-7. [PMID: 19824083 DOI: 10.1002/cncr.24682] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Virtually all staging schemes aimed at predicting the prognosis of surgically treated patients diagnosed with metastatic renal cell carcinoma (MRCC) omit the use of lymph node stage. In the current study, the authors tested the prognostic significance of lymph node stage in patients with MRCC within a population-based cohort of patients treated with cytoreductive nephrectomy to assess whether the inclusion of lymph node stage could improve the accuracy of cancer-specific mortality predictions. METHODS Within the Surveillance, Epidemiology, and End Results database, the authors identified 1153 patients who were treated with cytoreductive nephrectomy for MRCC, with (negative lymph nodes [N0] vs positive lymph nodes [N1-2]) or without (unknown lymph node stage [Nx]) lymphadenectomy. Of 797 patients treated with lymphadenectomy, 42.9% were found to have lymph node metastases. Kaplan-Meier plots and univariate and multivariate Cox regression analyses tested the statistical significance and the independent predictor status of lymph node stage, Fuhrman grade, tumor size, year of surgery, race, sex, and age in patients who underwent lymphadenectomy at the time of cytoreductive nephrectomy. RESULTS At 3 years after cytoreductive nephrectomy, the cancer-specific mortality-free rates of N1-2 versus N0 versus Nx patients were 14.4% versus 34.7% versus 34.0%, respectively. Lymph node stage represented the most informative variable and achieved independent predictor status in all multivariate models (P<.001). Consideration of lymph node stage added 3.2% accuracy to other predictors of cancer-specific mortality. CONCLUSIONS The findings of the current study indicate that lymph node stage should be considered in prognostic models. The TNM staging of MRCC patients also should rely on the stage of locoregional lymph nodes, because the 3-year cancer-specific mortality rates of lymph node-negative and lymph node-positive MRCC patients differ by as much as 20%.
Collapse
|
308
|
Isbarn H, Crepel M, Lughezzani G, Sun M, Karakiewicz PI. Reply. Urology 2010. [DOI: 10.1016/j.urology.2009.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
309
|
Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, Shariat SF, Crépel M, Alasker A, Widmer H, Arjane P, Patard JJ, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU Int 2010; 105:359-64. [DOI: 10.1111/j.1464-410x.2009.08745.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
310
|
Bigot P, Lughezzani G, Karakiewicz P, Perrotte P, Rioux-Leclercq N, Catros-Quemener V, Bouet F, Moulinoux JP, Cipolla B, Patard JJ. The Prognostic Value of Erythrocyte Polyamine in the Post-Nephrectomy Stratification of Renal Cell Carcinoma Specific Mortality. J Urol 2010; 183:486-91. [DOI: 10.1016/j.juro.2009.10.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Indexed: 11/17/2022]
|
311
|
Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010; 46:713-9. [PMID: 20044246 DOI: 10.1016/j.ejca.2009.12.007] [Citation(s) in RCA: 139] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2009] [Revised: 11/26/2009] [Accepted: 12/01/2009] [Indexed: 10/20/2022]
Abstract
BACKGROUND A reclassification of the International Union Against Cancer (UICC) staging system for adrenocortical carcinoma (ACC) patients has recently been proposed by the European Network for the Study of Adrenal Tumors (ENSAT) to better discriminate between cancer-specific mortality (CSM) risk strata. We formally tested the validity of the modified staging system in a large North American population-based cohort. METHODS Kaplan-Meier survival curves depicted CSM rates in the overall population and after stratification according to the 2004 UICC or the 2008 ENSAT-staging system. Cox regression models addressing CSM tested the prognostic value of respectively the UICC or the ENSAT-staging system. Harrell's concordance index quantified the accuracy of the standard versus the modified staging system. RESULTS In the overall population (n=573), the CSM-free survival rates at 1, 3, and 5 years were, respectively, 62.9%, 47.0%, and 38.1%. No statistically significant differences in survival were recorded between 2004 UICC stages II and III patients (p=0.1). Conversely, a statistically significant difference was observed between 2008 ENSAT stage II and stage III patients (p<0.001). The 2008 ENSAT-staging system showed higher accuracy (83.0%) in predicting 3-year CSM rates, relative to the 2004 UICC-staging system (79.5%) (p<0.001). CONCLUSION Our study corroborates the superior accuracy of the ENSAT-staging system for ACC relative to the 2004 UICC-staging system. In consequence, the 2008 ENSAT-staging system may warrant consideration in the next update of staging manuals.
Collapse
|
312
|
Lughezzani G, Budäus L, Isbarn H, Sun M, Perrotte P, Haese A, Chun FK, Schlomm T, Steuber T, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2009; 57:562-8. [PMID: 20018437 DOI: 10.1016/j.eururo.2009.12.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2009] [Accepted: 12/03/2009] [Indexed: 10/20/2022]
Abstract
BACKGROUND Several models can predict the rate of biochemical recurrence (BCR) after radical prostatectomy (RP). OBJECTIVE We tested the three most commonly used models-the D'Amico risk stratification scheme, the Cancer of the Prostate Risk Assessment (CAPRA) score, and the Stephenson nomogram-in a European cohort of RP patients. DESIGN, SETTING, AND PARTICIPANTS We relied on preoperative characteristics and prostate-specific antigen follow-up data of 1976 patients, as required by the three tested models. All patients were treated with an open RP between 1992 and 2006. MEASUREMENTS Analyses included tests of accuracy (Harrell's concordance index) and calibration between predicted and observed BCR rates at 3 yr and 5 yr after RP. Additionally, we relied on decision curve analyses to compare the three models directly in a head-to-head fashion. RESULTS AND LIMITATIONS The median follow-up of censored patients was 32 mo. BCR-free rates at 3 yr and 5 yr after RP were 80.2% and 72.6%, respectively. The concordance index for 3-yr BCR predictions was 70.4%, 74.3%, and 75.2% for the D'Amico, CAPRA, and Stephenson models, respectively, versus 67.4%, 72.9%, and 73.5% for 5-yr BCR predictions. Calibration results supported the use of either the CAPRA or Stephenson models. Decision curve analyses indicated a small benefit for the CAPRA score relative to the Stephenson nomogram. Our findings apply to German patients treated with RP at a high-volume tertiary care centre. Consequently, the rank order reported in this paper may not be the same in North American or other European cohorts. CONCLUSIONS Different methods yield different results, and it may be difficult to reconcile concordance index, calibration, and decision curve analysis findings. Our data suggest that the CAPRA score outperforms the other models when decision curve analysis and calibration were used as benchmarks. Conversely, the Stephenson nomogram outperformed the other models when concordance index was used as a metric.
Collapse
|
313
|
Lughezzani G, Sun M, Perrotte P, Shariat SF, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. Eur Urol 2009; 57:956-62. [PMID: 20018438 DOI: 10.1016/j.eururo.2009.12.001] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2009] [Accepted: 12/01/2009] [Indexed: 11/25/2022]
Abstract
BACKGROUND A large, multi-institutional, tertiary care center study suggested no benefit from bladder cuff excision (BCE) at nephroureterectomy in patients with upper tract urothelial carcinoma (UC). OBJECTIVE We tested and quantified the prognostic impact of BCE at nephroureterectomy on cancer-specific mortality (CSM) in a large population-based cohort of patients with UC of the renal pelvis. DESIGN, SETTING, AND PARTICIPANTS A cohort of 4210 patients with UC of the renal pelvis were treated with nephroureterectomy with (NUC) or without (NU) a BCE between 1988 and 2006 within 17 Surveillance, Epidemiology, and End Results registries. MEASUREMENTS Cumulative incidence plots and competing risks regression models compared CSM after either NUC or NU. Covariates consisted of pathologic T and N stages, grade, age, year of surgery, gender, and race. RESULTS AND LIMITATIONS Respectively, 2492 (59.2%) and 1718 (40.8%) patients underwent a nephroureterectomy with or without BCE. In univariable and multivariable analyses, BCE omission increased CSM rates in patients with pT3N0/x, pT4N0/x, and pT(any)N1-3 UC of the renal pelvis. For example, in patients with pT3N0/x disease, holding all other variables constant, BCE omission increased CSM in a 1.25-fold fashion (p=0.04). Similarly, in patients with pT4N0/x disease, BCE omission resulted in a 1.45-fold increase (p=0.02). The main limitation of our study is the lack of data on disease recurrence. CONCLUSIONS Nephroureterectomy with BCE remains the standard of care in the treatment of UC of the renal pelvis and should invariably be performed in patients with locally advanced disease. Conversely, patients with pT1 and pT2 disease could be considered for NU without compromising CSM. However, recurrence data are needed to fully confirm the validity of this option.
Collapse
|
314
|
Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, Shariat SF, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology 2009; 75:315-20. [PMID: 19963237 DOI: 10.1016/j.urology.2009.10.004] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Revised: 09/17/2009] [Accepted: 10/04/2009] [Indexed: 01/12/2023]
Abstract
OBJECTIVES To examine the perioperative mortality rates at 90 days (90 dM) after nephroureterectomy (NU) and to devise a model capable of identifying individuals at an elevated 90 dM risk. NU represents the surgical standard of care for patients with invasive, nonmetastatic upper-tract urothelial carcinoma. However, this major abdominal surgery may be associated with a nonnegligible rate of perioperative mortality. METHODS We identified 6078 upper-tract urothelial carcinoma patients treated with NU from 17 registries of the Surveillance, Epidemiology, and End Results database, between 1988 and 2006. Stratified analyses quantified 90 dM rates according to age, gender, race, year of diagnosis, tumor location, surgery type, T stage, tumor grade, and lymph node status. Subsequently, multivariable logistic regression models identified predictors of 90 dM within the development cohort (n = 3039). The accuracy and calibration of the model were tested in an independent validation cohort (n = 3039). RESULTS The overall 90 dM rate was 4.4%. Continuously coded age and T and N stages achieved an independent predictor status in multivariable logistic regression models and represented key variables for prediction of individual 90 dM risk after NU, with 73.4% accuracy. Excellent correlation between predicted and observed 90 dM rates after NU was recorded. CONCLUSIONS In this large-scale population-based analysis of perioperative mortality after NU, age and T and N stages emerged as the most informative predictor of 90 dM. We recommend the use of this tool in individual decision-making and in informed consent considerations.
Collapse
|
315
|
Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat SF, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology 2009; 75:271-5. [PMID: 19962740 DOI: 10.1016/j.urology.2009.04.098] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Revised: 03/24/2009] [Accepted: 04/22/2009] [Indexed: 01/08/2023]
Abstract
OBJECTIVES To test the effect of nephron-sparing surgery (NSS) vs radical nephrectomy (RN) on cancer-specific mortality (CSM) in patients with T1bN0M0 renal cell carcinoma (RCC) in a population-based cohort. To date, only few series from tertiary care centers supported the use of NSS for T1bN0M0 (range 4-7 cm) RCC. METHODS The Surveillance, Epidemiology, and End Results database allowed us to identify 275 NSS (5.3%) and 4866 RN (94.7%) patients treated for T1bN0M0 RCC between 1988 and 2004. Analyses matched for age, year of surgery, tumor size, and Fuhrman grade addressed the effect of nephrectomy type (NSS vs RN) on CSM. RESULTS Five years after surgery, the surviving proportions of NSS and RN patients matched for age, tumor size, and year of surgery were respectively 91.4 and 95.3% and 90.1 and 93.8% in the cohort, where additional matching for Fuhrman grade was performed. Neither of the matched analyses resulted in statistically significant CSM difference (P = .1 and .4) between NSS and RN. Similarly, competing-risks regression analyses based on both matching schemes also failed to reveal statistically significant CSM differences (P = .3 and .3). CONCLUSIONS Our study represents the largest and the only population-based analysis of cancer control efficacy of NSS vs RN in T1bN0M0 RCC. It indicates that NSS does provide equivalent cancer control relative to RN. In consequence, based on cancer control equivalence, NSS should be given equal consideration to RN in patients with T1bN0M0 lesions.
Collapse
|
316
|
Lughezzani G, Sun M, Perrotte P, Shariat SF, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz PI. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology 2009; 75:321-7. [PMID: 19962727 DOI: 10.1016/j.urology.2009.09.048] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2009] [Revised: 09/12/2009] [Accepted: 09/25/2009] [Indexed: 12/14/2022]
Abstract
OBJECTIVES To examine the effect of gender in upper tract urothelial carcinoma (UTUC) stage at nephroureterectomy (NU), as well as on cancer-specific mortality (CSM) after NU in patients with American Joint Committee on Cancer stages I-III UTUC. METHODS Our analyses relied on 2903 (59.9%) males and 1947 (40.1%) females who underwent an NU for pT(1-3)N(0/x)M(0) UTUC between 1988 and 2006, within 17 Surveillance, Epidemiology, and End Results registries. Univariable and multivariable logistic regression models examined the effect of gender on stage and grade distribution at NU. Subsequently, cumulative incidence plots explored the impact of gender on CSM rates, after accounting for other-cause mortality (OCM). Finally, competing-risks regression models tested the independent predictor status of gender in CSM analyses. Covariates consisted of pT stage, pN stage, tumor grade, primary tumor location, type and year of surgery, age, and race. RESULTS Relative to males, females had a higher proportion of pT(3) UTUC (43.1% vs 39%; P = .02) and a higher proportion of grade III/IV UTUC (63.8% vs 59.8%; P = .04) at NU. The female gender represented an independent predictor of pT(3) UTUC at NU (hazard ratio [HR]: 1.15; P = .03). After accounting for OCM, CSM rates in females were higher than those in males (HR: 1.18; P = .03). However, in multivariable competing-risks regression models, no statistically significant differences in survival were recorded between males and females (HR: 1.07; P = .4). CONCLUSIONS Females are more likely to have more advanced pathologic T stage and higher tumor grade at NU than males. After accounting for OCM, stage, grade, and noncancer characteristics, gender no longer affects CSM.
Collapse
|
317
|
Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients. Eur J Cancer 2009; 45:3291-7. [DOI: 10.1016/j.ejca.2009.06.016] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2009] [Revised: 06/07/2009] [Accepted: 06/12/2009] [Indexed: 10/20/2022]
|
318
|
Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int 2009; 104:1661-7. [DOI: 10.1111/j.1464-410x.2009.08660.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
319
|
Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, Valeri A, Cindolo L, Ficarra V, Artibani W, Zigeuner R, Mejean A, Descotes JL, Lechevallier E, Mulders PF, Perrotte P, Patard JJ, Karakiewicz PI. Can Renal Mass Biopsy Assessment of Tumor Grade be Safely Substituted for by a Predictive Model? J Urol 2009; 182:2585-9. [PMID: 19836799 DOI: 10.1016/j.juro.2009.08.053] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2009] [Indexed: 11/16/2022]
|
320
|
Sun M, Lughezzani G, Latour M, Karakiewicz PI. Reply from Authors re: Vincenzo Ficarra, Giacomo Novara, Guido Martignoni. The Use of Simplified Versions of the Fuhrman Nuclear Grading System in Clinical Practice Requires the Agreement of a Multidisciplinary Panel of Experts. Eur Urol 2009;56:782–4. Eur Urol 2009. [DOI: 10.1016/j.eururo.2009.07.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
321
|
Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2009; 75:118-24. [PMID: 19864000 DOI: 10.1016/j.urology.2009.07.1296] [Citation(s) in RCA: 113] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2009] [Revised: 06/30/2009] [Accepted: 07/09/2009] [Indexed: 01/26/2023]
Abstract
OBJECTIVES To perform a population-based analysis of the potential staging or prognostic value (or both) of lymph node dissection (LND) in patients without nodal metastases vs no LND. In several previous reports, LND in patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy (NU) was associated with better survival relative to no LND (pN(x)), even in the absence of pathologically confirmed nodal metastases (pN(0)). METHODS Within the surveillance, epidemiology, and end results database, we identified 2824 patients treated with NU for UTUC between 1988 and 2004. CSM rates after NU were graphically explored using Kaplan-Meier plots. Univariable and multivariable Cox regression models tested the effect of N(0) vs N(x) stage on CSM, after adjusting for T stage, tumor grade, age, gender, primary tumor location, type, and year of surgery. RESULTS The CSM-free survival rate at 5 years after NU was 81.2% and 77.8% respectively for pN(0) and pN(x) patients. In univariable analyses pN(x) vs pN(0) status was not associated with worse survival (HR: 1.19; P = .09). After adjustment for all covariates, pN(x) vs pN(0) status still failed to achieve independent predictor status (HR: 0.99; P = .9). CONCLUSIONS We found no survival benefit related to the performance of LND in pN(0) patients, relative to pN(x) patients. Lack of standardized criteria for patients' selection for LND and for pathological lymph node specimen evaluation represents some of the explanation for the observed discrepancy between the current finding and previous findings.
Collapse
|
322
|
Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, Shariat SF, Sun M, Lughezzani G, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States. Urology 2009; 74:837-41. [DOI: 10.1016/j.urology.2009.04.019] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2008] [Revised: 03/13/2009] [Accepted: 04/01/2009] [Indexed: 11/28/2022]
|
323
|
Mottrie A, Buffi N, Lughezzani G, Denaeyer G, Schatteman P, Carpentier P, Fonteyne E. Female robotic radical cystectomy. BJU Int 2009; 104:1024-35. [DOI: 10.1111/j.1464-410x.2009.08877.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
324
|
Isbarn H, Capitanio U, Lughezzani G, Karakiewicz PI. Reply. Urology 2009. [DOI: 10.1016/j.urology.2009.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
325
|
Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 2009; 182:2177-81. [PMID: 19758662 DOI: 10.1016/j.juro.2009.07.035] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2009] [Indexed: 11/16/2022]
Abstract
PURPOSE The prognostic significance of renal pelvis vs ureteral upper urinary tract urothelial carcinoma tumor location is controversial. We assessed the prognostic significance of upper urinary tract urothelial carcinoma tumor location in a large, population based data set. MATERIALS AND METHODS Our analyses relied on 2,824 patients treated with nephroureterectomy for upper urinary tract urothelial carcinoma within 9 SEER registries between 1988 and 2004. Univariable and multivariable models tested the effect of tumor location on cancer specific mortality rates. Covariates consisted of age, race, SEER registry, gender, type of surgery (nephroureterectomy with vs without bladder cuff removal), pT stage, pN stage, grade and year of surgery. RESULTS Relative to ureteral tumors renal pelvis tumors were of higher stage (T3/T4 disease 38.4% vs 57.9%, p <0.001) and had a higher rate of lymph node metastases (6.0% vs 9.8%, p = 0.003) at nephroureterectomy. The respective 5-year cancer specific mortality-free survival estimates were 81.0% vs 75.5% (p = 0.007). However, after multivariable adjustment tumor location failed to reach independent predictor status of cancer specific mortality (p = 0.8). CONCLUSIONS To our knowledge this is the largest cohort in which the impact of upper urinary tract urothelial carcinoma tumor location on cancer specific mortality was examined. At nephroureterectomy renal pelvis tumors had significantly more advanced T and N stages compared to ureteral tumors. However, after adjustment for stage, grade and other covariates tumor location did not independently predict cancer specific mortality. Thus, the biological behavior of renal pelvis vs ureteral tumors is the same after nephroureterectomy as long as stage, grade, and other patient and tumor characteristics are accounted for.
Collapse
|